查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1636768

2030 年篩檢檢測市場預測：按檢測類型、性別、最終用戶和地區進行的全球分析

Breast Cancer Screening Tests Market Forecasts to 2030 - Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球篩檢篩檢市場預計在 2024 年達到 22.9 億美元，到 2030 年預計將達到 40.1 億美元，預測期內的複合年成長率為 9.8%。

篩檢測試是一種用於在未表現出症狀的個體中檢測乳癌早期跡象的醫療程序。主要的篩檢方法包括乳房X光攝影、超音波、核磁共振成像和3D乳房X光攝影（斷層合成）。這些檢查旨在識別乳房組織的異常生長或變化，以便儘早診斷和治療。定期篩檢可以在早期、更易治療的階段發現腫瘤，有助於提高存活率，尤其是對於乳癌高風險族群。

根據歐洲乳癌聯盟 2023 年的預測，乳癌將成為 2023 年歐洲最常見的癌症，新增病例約 38 萬例，主要發生在女性身上。

提高早期檢測意識

提高人們對早期檢測的認知對於篩檢測試市場的擴大至關重要。隨著越來越多的人意識到早期發現癌症的重要性，對篩檢服務的需求急劇增加。醫療保健宣傳活動、媒體關注和教育活動正在強調早期檢測的救命益處。由於這些認知，篩檢計畫的參與人數增加，尤其是在高風險族群。許多篩檢方法，包括乳房X光攝影、核磁共振成像和超音波，都被廣泛使用，因為透過定期篩檢進行早期發現可以改善治療效果和存活率。

輻射暴露問題

對輻射暴露的擔憂是乳癌篩檢技術市場發展的一大障礙，尤其是當乳房 X乳房X光攝影等標準程序使用低劑量的 X 光時。雖然乳房X光攝影中使用的輻射量較低且對大多數女性來說是安全的，但長期暴露會對健康造成風險，包括增加罹患癌症的風險。對於某些女性，尤其是年輕女性或有家族病史的女性來說，這些擔憂可能會阻礙她們進行頻繁的篩檢。目前正在研究替代性的無輻射篩檢方法，例如 MRI 和超音波，以降低這些風險並確保有效的早期檢測。

提高對遺傳風險因子的認知

人們對遺傳風險（尤其是與 BRCA1 和 BRCA2 基因突變相關的遺傳風險）認知的提高，使得更多人選擇早期篩檢和基因檢測。因此，建議女性，特別是有乳癌家族病史的女性，從小就定期進行篩檢。遺傳諮詢結合MRI和乳房X光攝影等篩檢測試，可以識別高風險患者並促進早期發現和主動監測。隨著人們認知的提高，對更好的篩檢技術和基因檢測的需求也在增加。

缺乏熟練的醫療保健專業人員

合格醫護人員，尤其是放射科醫師和技術人員的短缺，是篩檢篩檢市場發展的一大障礙。需要高素質的專家來準確地解釋乳房X光攝影等篩檢資料，而缺乏專家可能會導致診斷延遲和篩檢效果降低。缺乏訓練有素的工作人員限制了許多地區，特別是農村和貧困社區獲得及時檢測的機會，對早期檢測工作產生了負面影響。這種短缺進一步給醫療保健系統帶來了壓力，凸顯了資助教育計畫和創建人工智慧診斷技術以協助醫療保健工作者的必要性。

COVID-19 的影響

COVID-19 疫情嚴重擾亂了乳癌篩檢市場。這是因為許多醫療機構已暫停常規篩檢，以優先治療 COVID-19。這可能會導致早期檢測延遲並影響患者的治療結果。此外，對被鎖在門外或接觸病毒的恐懼也使人們不願尋求篩檢服務。然而，隨著醫療保健系統的適應，包括實施安全措施、增加遠端醫療的使用以及注重恢復延遲的篩檢以進行早期診斷，經濟正在逐步復甦。

預測期內，影像檢查領域預計將成為最大的市場

受 3D乳房X光攝影、MRI 和超音波等診斷技術的進步推動，影像檢查領域估計是最大的領域。這些影像檢查可以提高準確性，更早發現腫瘤，並區分良性和惡性腫瘤。此外，乳癌發生率的不斷上升以及早期檢測意識的增強也推動了影像檢查的普及。技術創新、影像解析度的提高以及人工智慧的融合正在進一步提高影像在乳癌診斷中的有效性。

預測期內，診斷實驗室部門預計將以最高複合年成長率成長

由於使用乳房X光攝影、超音波和 MRI 等先進技術提供專業診斷服務，預計診斷實驗室部門將在預測期內實現最高的複合年成長率。對準確和早期乳癌檢測的需求不斷成長，推動了診斷實驗室的發展。此外，醫療基礎設施的改善和乳癌預防意識的增強也導致了患者數量的增加。實驗室提供及時準確的診斷結果的能力對於乳癌的早期發現和治療越來越重要。

比最大的地區

由於醫療保健意識的增強、乳癌發病率的上升以及可支配收入的增加，預計亞太地區將在預測期內佔據最大的市場佔有率。快速的都市化和不斷改善的醫療保健基礎設施使得篩檢服務更加容易獲得。在日本、中國和印度等國家，政府採取措施和篩選計畫促進早期發現。此外，人們對女性健康意識的不斷提高和診斷技術的進步進一步推動了該全部區域乳癌篩檢測試的採用。

複合年成長率最高的地區：

受高標準醫療保健、強力的政府支持和先進的醫療技術等因素推動，預計北美地區在預測期內將實現最高的複合年成長率。廣泛的篩檢項目，包括乳房X光攝影和核磁共振成像，鼓勵早期發現和預防護理。人們對乳癌的認知不斷提高，加上醫療保險覆蓋範圍的擴大，正在鼓勵人們定期進行乳癌篩檢。此外，人口老化、高可支配收入以及獲得尖端診斷工具的機會也促進了北美市場的成長。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業進行基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球篩檢測試市場（依測試類型）

  • 血液檢查
  • 影像檢查
    • 乳房X光檢查
    • 磁振造影（MRI）
    • 正子斷層掃描
    • 超音波
  • 基因檢測
    • 螢光原位雜合反應
    • HER基因檢測
  • 切片檢查
  • 斷層合成
  • 其他測試類型

6. 全球篩檢篩檢市場（依性別）

  • 男性
  • 女士

7. 全球篩檢檢測市場（以最終用戶分類）

  • 診斷實驗室
  • 醫院
  • 專科門診
  • 癌症研究所
  • 研究實驗室
  • 其他最終用戶

8. 全球乳癌篩檢檢測市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章 主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司概況

  • GE Healthcare
  • Hologic, Inc.
  • Siemens Healthineers
  • Philips Healthcare
  • Canon Medical Systems Corporation
  • Koninklijke Philips NV
  • Fujifilm Holdings Corporation
  • IQM Diagnostics
  • Medtronic PLC
  • 3M Health Care
  • Samsung Medison Co., Ltd.
  • Carestream Health, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Volpara Health Technologies
  • Medimaps Group
  • Dilon Technologies, Inc.
  • LumaVision
  • Aurora Imaging Technology, Inc.
Product Code: SMRC28410

According to Stratistics MRC, the Global Breast Cancer Screening Tests Market is accounted for $2.29 billion in 2024 and is expected to reach $4.01 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Breast cancer screening tests are medical procedures used to detect early signs of breast cancer in individuals who show no symptoms. The primary screening methods include mammography, ultrasound, MRI, and 3D mammography (tomosynthesis). These tests aim to identify abnormal growths or changes in breast tissue, allowing for early diagnosis and treatment. Regular screening helps improve survival rates by detecting tumours at an earlier, more treatable stage, especially in individuals at higher risk for breast cancer.

According to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women.

Market Dynamics:

Driver:

Increasing awareness of early detection

Growing awareness of early detection is essential to the market expansion for breast cancer screening tests. Demand for screening services has increased dramatically as more individuals realize how important it is to detect cancer in its early stages. Health organizations' campaigning, media attention, and educational efforts have highlighted the life-saving advantages of early identification. Participation in screening programs has increased as a result of this knowledge, particularly among high-risk groups. Numerous screening techniques, including mammography, MRI, and ultrasound, are being used by a wide range of demographics due to the fact that early identification through routine screening improves treatment results and survival rates.

Restraint:

Radiation exposure concerns

Concerns about radiation exposure present a major obstacle to the market for breast cancer screening technologies, especially when using low-dose X-rays in standard procedures like mammography. Even while the radiation used in mammograms is considered to be low and safe for the majority of women, prolonged exposure might cause health hazards, such as an elevated risk of cancer. Particularly for younger women or those with a family history of cancer, these worries may discourage some people from getting frequent checkups. Alternative, non-radiative screening techniques like MRI and ultrasound are now being investigated in an effort to lower these hazards and guarantee efficient early identification.

Opportunity:

Rising awareness of genetic risk factors

Growing awareness of genetic risks, especially those associated with mutations in the BRCA1 and BRCA2 genes, has led to an increase in the number of people choosing early screening and genetic testing. Women are encouraged to get regular screenings at a younger age because of this awareness, particularly those who have a family history of breast cancer. When paired with screening procedures like MRIs and mammograms, genetic counseling assists in identifying high-risk patients, facilitating early detection and proactive monitoring. The need for better screening techniques and genetic testing is increasing along with awareness.

Threat:

Shortage of skilled healthcare professionals

The lack of qualified medical personnel, especially radiologists and technicians, is a major obstacle in the market for breast cancer screening testing. It takes highly qualified specialists to accurately interpret screening data, such mammograms, and their absence can cause delays in diagnosis and decreased screening efficacy. The lack of trained staff restricts access to timely tests in many areas, particularly in rural or underprivileged areas, which has a detrimental effect on early detection initiatives. Healthcare systems are further burdened by this scarcity, underscoring the necessity of funding educational initiatives and the creation of AI-powered diagnostic technologies to assist medical practitioners.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the breast cancer screening tests market, as many healthcare facilities temporarily suspended routine screenings to prioritize COVID-19 care. This led to delays in early detection, potentially affecting patient outcomes. Additionally, lockdowns and fear of exposure to the virus discouraged individuals from seeking screening services. However, as healthcare systems adapt, there has been a gradual recovery with the implementation of safety measures, increased use of telemedicine, and a focus on resuming delayed screenings for early diagnosis.

The imaging test segment is expected to be the largest during the forecast period

The imaging test segment is estimated to be the largest, driven by advancements in diagnostic technologies, such as 3D mammography, MRI, and ultrasound. These imaging tests provide higher accuracy, early detection of tumours, and better differentiation between benign and malignant growths. Additionally, the increasing prevalence of breast cancer, along with rising awareness of early detection, fuels the adoption of imaging tests. Technological innovations, improved image resolution, and integration of artificial intelligence further enhance the effectiveness of imaging in breast cancer diagnosis.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is anticipated to witness the highest CAGR during the forecast period, as they provide specialized diagnostic services using advanced technologies like mammography, ultrasound, and MRI. The increasing demand for accurate and early breast cancer detection fuels growth in diagnostic labs. Additionally, improved healthcare infrastructure and rising awareness of breast cancer prevention contribute to higher patient volumes. Laboratories' ability to offer timely and precise diagnostic results further enhances their importance in the early detection and treatment of breast cancer.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to growing healthcare awareness, increasing breast cancer prevalence, and rising disposable incomes. Rapid urbanization and improvements in healthcare infrastructure are making screening services more accessible. Government initiatives and screening programs in countries like Japan, China, and India are promoting early detection. Additionally, a rising focus on women's health, coupled with advancements in diagnostic technologies, further boosts the adoption of breast cancer screening tests across the region.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fueled by factors such as high healthcare standards, strong government support, and advanced medical technologies. The widespread availability of screening programs, including mammography and MRI, encourages early detection and preventive care. Rising awareness about breast cancer, coupled with increased health insurance coverage, promotes regular screenings. Additionally, the aging population, high disposable incomes, and access to cutting-edge diagnostic tools further contribute to the market's growth in North America.

Key players in the market

Some of the key players profiled in the Breast Cancer Screening Tests Market include GE Healthcare, Hologic, Inc., Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Koninklijke Philips N.V., Fujifilm Holdings Corporation, IQM Diagnostics, Medtronic PLC, 3M Health Care, Samsung Medison Co., Ltd., Carestream Health, Inc., Inovio Pharmaceuticals, Inc., Volpara Health Technologies, Medimaps Group, Dilon Technologies, Inc., LumaVision, and Aurora Imaging Technology, Inc.

Key Developments:

In March 2024, Philips strengthens strategic partnership with Sim&Cure to expand innovation in neurovascular therapy. Philips announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago.

In May 2024, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, announced it has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.

In March 2024, GE Healthcare Wipro, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years.

Test Types Covered:

  • Blood Tests
  • Imaging Test
  • Genetic Test
  • Biopsy
  • Tomosynthesis
  • Other Test Types

Genders Covered:

  • Male
  • Female

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Specialty Clinics
  • Cancer Institutes
  • Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Screening Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Blood Tests
  • 5.3 Imaging Test
    • 5.3.1 Mammography
    • 5.3.2 Magnetic Resonance Imaging (MRI)
    • 5.3.3 PET Scan
    • 5.3.4 Ultrasound
  • 5.4 Genetic Test
    • 5.4.1 Fluorescence In Situ Hybridization
    • 5.4.2 HER gene test
  • 5.5 Biopsy
  • 5.6 Tomosynthesis
  • 5.7 Other Test Types

6 Global Breast Cancer Screening Tests Market, By Gender

  • 6.1 Introduction
  • 6.2 Male
  • 6.3 Female

7 Global Breast Cancer Screening Tests Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals
  • 7.4 Specialty Clinics
  • 7.5 Cancer Institutes
  • 7.6 Research Laboratories
  • 7.7 Other End Users

8 Global Breast Cancer Screening Tests Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Hologic, Inc.
  • 10.3 Siemens Healthineers
  • 10.4 Philips Healthcare
  • 10.5 Canon Medical Systems Corporation
  • 10.6 Koninklijke Philips N.V.
  • 10.7 Fujifilm Holdings Corporation
  • 10.8 IQM Diagnostics
  • 10.9 Medtronic PLC
  • 10.10 3M Health Care
  • 10.11 Samsung Medison Co., Ltd.
  • 10.12 Carestream Health, Inc.
  • 10.13 Inovio Pharmaceuticals, Inc.
  • 10.14 Volpara Health Technologies
  • 10.15 Medimaps Group
  • 10.16 Dilon Technologies, Inc.
  • 10.17 LumaVision
  • 10.18 Aurora Imaging Technology, Inc.

List of Tables

  • Table 1 Global Breast Cancer Screening Tests Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 3 Global Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 4 Global Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 5 Global Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 6 Global Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 7 Global Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 8 Global Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 9 Global Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 10 Global Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 11 Global Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 12 Global Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 13 Global Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 14 Global Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 15 Global Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 16 Global Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 17 Global Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 18 Global Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 19 Global Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 20 Global Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 21 Global Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 22 Global Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 23 Global Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 24 Global Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 25 North America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 26 North America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 27 North America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 28 North America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 29 North America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 30 North America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 31 North America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 32 North America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 33 North America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 34 North America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 35 North America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 36 North America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 37 North America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 38 North America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 39 North America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 40 North America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 41 North America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 42 North America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 43 North America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 44 North America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 45 North America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 46 North America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 47 North America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 48 North America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Europe Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Europe Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 51 Europe Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 52 Europe Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 53 Europe Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 54 Europe Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 55 Europe Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 56 Europe Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 57 Europe Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 58 Europe Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 59 Europe Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 60 Europe Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 61 Europe Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 62 Europe Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 63 Europe Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 64 Europe Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 65 Europe Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 66 Europe Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 67 Europe Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 68 Europe Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 69 Europe Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 70 Europe Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 71 Europe Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 72 Europe Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 73 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 74 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 75 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 76 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 77 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 78 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 79 Asia Pacific Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 80 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 81 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 82 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 83 Asia Pacific Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 84 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 85 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 86 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 87 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 88 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 89 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 90 Asia Pacific Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 91 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 92 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 93 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 94 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 95 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 96 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 97 South America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 98 South America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 99 South America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 100 South America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 101 South America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 102 South America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 103 South America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 104 South America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 105 South America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 106 South America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 107 South America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 108 South America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 109 South America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 110 South America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 111 South America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 112 South America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 113 South America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 114 South America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 115 South America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 116 South America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 117 South America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 118 South America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 119 South America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 120 South America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 121 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 122 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 123 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 124 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 125 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 126 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 127 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 128 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 129 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 130 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 131 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 132 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 133 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 134 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 135 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 136 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 137 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 138 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 139 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 140 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 141 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 142 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 143 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 144 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)